Profile data is unavailable for this security.
About the company
Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).
- Revenue in USD (TTM)0.00
- Net income in USD-7.20m
- Incorporated2004
- Employees4.00
- LocationOruka Therapeutics Inc10170 Church Ranch Way, Suite 100WESTMINSTER 80021United StatesUSA
- Phone+1 (720) 940-2200
- Fax+1 (302) 655-5049
- Websitehttps://orukatx.com/
Mergers & acquisitions
Acquired company | ORKA:NMQ since announced | Transaction value |
---|---|---|
Oruka Therapeutics Inc | 24.12% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuvation Bio Inc | 1.44m | -510.72m | 806.82m | 167.00 | -- | 2.05 | -- | 562.24 | -2.11 | -2.11 | 0.0064 | 2.43 | 0.0023 | -- | 0.4216 | 28,137.26 | -82.63 | -16.27 | -87.18 | -16.65 | 6.13 | -- | -35,590.24 | -- | -- | -- | 0.0214 | -- | -- | -- | 27.25 | -- | -- | -- |
Adaptive Biotechnologies Corp | 168.77m | -213.47m | 814.05m | 709.00 | -- | 3.37 | -- | 4.82 | -1.47 | -1.47 | 1.16 | 1.64 | 0.2501 | 4.74 | 5.03 | 238,033.80 | -31.65 | -19.69 | -36.63 | -22.06 | 54.77 | 67.18 | -126.55 | -122.27 | 3.84 | -- | 0.3536 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
CARGO Therapeutics Inc | 0.00 | -147.71m | 815.73m | 116.00 | -- | 1.87 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
Dianthus Therapeutics Inc | 4.12m | -56.68m | 821.92m | 53.00 | -- | 2.29 | -- | 199.59 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
MiMedx Group Inc | 340.46m | 89.67m | 845.62m | 895.00 | 11.53 | 5.03 | 8.62 | 2.48 | 0.4996 | 0.4622 | 2.08 | 1.15 | 1.67 | 2.70 | 6.69 | 380,402.30 | 48.16 | -4.14 | 60.79 | -5.90 | 83.41 | 83.61 | 28.76 | -2.70 | 3.22 | 13.06 | 0.1028 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
Silence Therapeutics plc | 23.48m | -52.59m | 869.74m | 115.00 | -- | 5.90 | -- | 37.04 | -0.4228 | -0.4228 | 0.1875 | 1.05 | 0.1273 | -- | 2.56 | 204,164.10 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Applied Therapeutics Inc | -333.00k | -161.09m | 884.32m | 31.00 | -- | 12.22 | -- | -- | -1.52 | -1.52 | -0.0029 | 0.6303 | -0.0039 | -- | -- | -13,320.00 | -187.94 | -140.37 | -467.74 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
Oruka Therapeutics Inc | 0.00 | -7.20m | 891.41m | 4.00 | -- | 0.9453 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
Zymeworks Inc | 62.71m | -112.51m | 893.07m | 290.00 | -- | 2.21 | -- | 14.24 | -1.52 | -1.52 | 0.8531 | 5.69 | 0.1122 | -- | 1.55 | 230,533.10 | -20.13 | -22.58 | -23.21 | -26.90 | -- | -- | -179.42 | -91.17 | -- | -- | 0.00008 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Perspective Therapeutics Inc | -1.87m | -49.02m | 900.16m | 116.00 | -- | 2.64 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
Prothena Corporation PLC | 217.25m | -50.92m | 906.74m | 173.00 | -- | 1.56 | -- | 4.17 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
IGM Biosciences Inc | 2.91m | -220.40m | 914.10m | 204.00 | -- | 7.46 | -- | 314.02 | -3.67 | -3.67 | 0.0485 | 2.07 | 0.0071 | -- | -- | 12,995.54 | -53.94 | -44.66 | -59.96 | -48.20 | -- | -- | -7,571.35 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
Arrivent Biopharma Inc | 0.00 | -74.89m | 915.55m | 40.00 | -- | 3.08 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Sana Biotechnology Inc | 0.00 | -244.90m | 941.03m | 328.00 | -- | 2.77 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Cullinan Therapeutics Inc | 0.00 | -142.16m | 947.34m | 85.00 | -- | 1.44 | -- | -- | -3.10 | -3.10 | 0.00 | 11.34 | 0.00 | -- | -- | 0.00 | -23.96 | -12.37 | -24.85 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Holder | Shares | % Held |
---|---|---|
Cable Car Capital LLCas of 31 Mar 2024 | 4.00m | 27.58% |
Janus Henderson Investors UK Ltd.as of 25 Jul 2024 | 2.11m | 14.55% |
Western Standard LLCas of 31 Mar 2024 | 1.41m | 9.72% |
Adage Capital Management LPas of 03 Apr 2024 | 1.20m | 8.27% |
Allostery Investments LPas of 15 Apr 2024 | 1.07m | 7.34% |
Avidity Partners Management LPas of 03 Apr 2024 | 1.00m | 6.89% |
TD Securities (USA) LLCas of 30 Jun 2024 | 700.00k | 4.83% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 453.60k | 3.13% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 231.24k | 1.59% |
Geode Capital Management LLCas of 30 Jun 2024 | 161.74k | 1.12% |